IL151627A0 - Divided dose therapies with vascular damaging activity - Google Patents

Divided dose therapies with vascular damaging activity

Info

Publication number
IL151627A0
IL151627A0 IL15162701A IL15162701A IL151627A0 IL 151627 A0 IL151627 A0 IL 151627A0 IL 15162701 A IL15162701 A IL 15162701A IL 15162701 A IL15162701 A IL 15162701A IL 151627 A0 IL151627 A0 IL 151627A0
Authority
IL
Israel
Prior art keywords
vascular damaging
divided dose
damaging activity
dose therapies
damaging agent
Prior art date
Application number
IL15162701A
Other languages
English (en)
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013928A external-priority patent/GB0013928D0/en
Priority claimed from GB0014904A external-priority patent/GB0014904D0/en
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of IL151627A0 publication Critical patent/IL151627A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL15162701A 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity IL151627A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013928A GB0013928D0 (en) 2000-06-08 2000-06-08 Methods of treatment
GB0014904A GB0014904D0 (en) 2000-06-20 2000-06-20 Methods of treatment
PCT/GB2001/001329 WO2001074369A1 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Publications (1)

Publication Number Publication Date
IL151627A0 true IL151627A0 (en) 2003-04-10

Family

ID=27255635

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15162701A IL151627A0 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Country Status (23)

Country Link
US (1) US20030055024A1 (xx)
EP (1) EP1272200B1 (xx)
JP (1) JP2003528921A (xx)
KR (1) KR20020084267A (xx)
CN (1) CN1422157A (xx)
AT (1) ATE298240T1 (xx)
AU (2) AU2001242586B2 (xx)
BR (1) BR0109671A (xx)
CA (1) CA2402078A1 (xx)
CZ (1) CZ20023231A3 (xx)
DE (1) DE60111622T2 (xx)
EE (1) EE200200549A (xx)
ES (1) ES2243466T3 (xx)
HU (1) HUP0300576A3 (xx)
IL (1) IL151627A0 (xx)
IS (1) IS6555A (xx)
MX (1) MXPA02009603A (xx)
NO (1) NO20024683L (xx)
NZ (1) NZ534190A (xx)
PL (1) PL357282A1 (xx)
PT (1) PT1272200E (xx)
SK (1) SK13902002A3 (xx)
WO (1) WO2001074369A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
US20060142239A1 (en) * 2003-06-18 2006-06-29 Ryan Anderson J Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67646A0 (en) * 1982-01-15 1983-05-15 Lilly Co Eli Ascorbic acid ethers and related compounds
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
AU6605690A (en) * 1989-10-27 1991-05-31 Du Pont Merck Pharmaceutical Company, The Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
US5326905A (en) * 1990-04-02 1994-07-05 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US6194439B1 (en) * 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH11228594A (ja) * 1998-02-16 1999-08-24 Meiji Milk Prod Co Ltd 新規プロゲステロン化合物
AU5717400A (en) * 1999-06-14 2001-01-02 Cancer Research Ventures Limited Cancer therapy
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent

Also Published As

Publication number Publication date
NO20024683D0 (no) 2002-09-30
ES2243466T3 (es) 2005-12-01
AU4258601A (en) 2001-10-15
CN1422157A (zh) 2003-06-04
KR20020084267A (ko) 2002-11-04
CZ20023231A3 (cs) 2003-01-15
NZ534190A (en) 2007-05-31
ATE298240T1 (de) 2005-07-15
HUP0300576A3 (en) 2005-02-28
US20030055024A1 (en) 2003-03-20
BR0109671A (pt) 2003-02-04
NO20024683L (no) 2002-10-15
PT1272200E (pt) 2005-09-30
WO2001074369A1 (en) 2001-10-11
DE60111622T2 (de) 2006-05-18
EP1272200A1 (en) 2003-01-08
AU2001242586B2 (en) 2004-12-16
PL357282A1 (en) 2004-07-26
DE60111622D1 (de) 2005-07-28
SK13902002A3 (sk) 2003-05-02
IS6555A (is) 2002-10-18
EE200200549A (et) 2004-02-16
EP1272200B1 (en) 2005-06-22
HUP0300576A2 (hu) 2003-07-28
CA2402078A1 (en) 2001-10-11
JP2003528921A (ja) 2003-09-30
MXPA02009603A (es) 2004-05-14

Similar Documents

Publication Publication Date Title
GB0223380D0 (en) Combination therapy
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
PT1933833E (pt) Terapia para o tratamento da bexiga superactiva
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
HK1130422A1 (en) A new use of deferiprone
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
IL151628A0 (en) Combination therapies with vascular damaging activity
NZ507203A (en) Use of dexmedetomidine for ICU sedation
GB0130677D0 (en) Medicaments and novel compounds
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
IL151627A0 (en) Divided dose therapies with vascular damaging activity
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
IL159770A0 (en) Calcium salts with cytotoxic activity
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
IL164092A0 (en) The use of devazepide as analgesic agent
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
GB0223379D0 (en) Combination therapy